The TearCare® System is a treatment alternative for dry eye patients who have dryness as a result of Meibomian Gland Disorder (MGD). MGD is a blockage or some form of dysfunction of the Meibomian glands

The Meibomian glands are located along the rims of the eyelid. They produce meibum, an oily substance that prevents evaporation of the eye’s tear film. TearCare® works by applying localized heat directly to the Meibomian glands to liquefy the meibum, remove blockages, and stimulate tear production.

How It Works

TearCare® is a personalized open-eye, in-office procedure designed to target the underlying cause of evaporative dry eye.

TearCare Animated Video from Sight Sciences on Vimeo.

TearCare® in Action

The TearCare® System is a blink-assisted device that utilizes both wearable and smart technology to deliver targeted thermal energy (heat) to the eyelids while allowing the eyelids to blink naturally.

TearCare® Education and Mentorship (TEaM)

TearCare® TEaM is a user and peer support program designed to share education, training, and experiences during the patient’s adoption of TearCare® technology. It also helps patients advance their skills and comfort in using TearCare®.

Indicated Use

TearCare® is indicated for patients who have Meibomian Gland Dysfunction (MGD), Dry Eye, or Blepharitis.

TearCare® Dry Eye Treatment at FSN Eye Center

If you are interested in TearCare® dry eye treatment, call FSN Eye Center at (815) 932-2020 to schedule an appointment. For your convenience, you may also request an appointment online.

TearCare® Dry Eye Treatment at FSN Eye Center

Unlike other dry eye treatments, TearCare® allows patients to keep their eyes open and they can blink throughout the procedure, which allows for more comfort during the procedure.

Also, TearCare® is a customizable system, allowing your eye doctor to adjust the settings as needed and treat any discomfort or side effects in the office.

Check with your individual insurance provider to see if TearCare® is covered as a dry eye treatment.

TearCare® can provide dry eye relief from Meibomian gland dysfunction for 6 months to a year.

Generally, TearCare® treatment can be administered every 3 months, but it depends on the patient’s needs.

TearCare® is contraindicated for patients with:

  • Recent (e.g. within the last 90 days) intraocular or periocular surgery
  • Recent ocular injury
  • Recent history of Ocular Herpes Simplex or Herpes Zoster
  • Active ocular or periocular infection or inflammation
  • Diminished or abnormal facial, periocular, ocular, or corneal sensation
  • Ocular surface ulcers

It is also not recommended for patients under the age of 22 years.

Potential adverse events associated with the use of the TearCare® System include the following:

  • Burn, erythema, swelling of the eyelids
  • Conjunctival infection (moderate or severe)
  • Conjunctival abrasion
  • Corneal abrasion
  • Corneal deformation
  • An allergic or inflammatory reaction to the medical adhesive on the SmartLid device
  • Formation of a chalazion or stye
  • A decline in visual acuity
  • Worsening of dry eye symptoms
  • Increased discomfort or pain of ocular surface (grittiness, foreign body sensation, etc.)
  • Discomfort or pain of eyelids or orbit